Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$139.01 USD

139.01
947,434

+0.87 (0.63%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $139.04 +0.03 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (171 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Shockwave Medical's (SWAV) Reducer Receives Positive Results

Shockwave Medical (SWAV) announces the 'real-world' results of the REDUCER-I study, which is intended to collect long-term outcomes on Shockwave Reducer, a novel treatment for refractory angina.

Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes

Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.

Here's Why Investors Should Retain Integra (IART) Stock Now

Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.

Thermo Fisher (TMO) Launches TSX Universal Series ULT Freezers

Thermo Fisher's (TMO) new ENERGY STAR-certified TSX Universal Series ULT Freezers deliver tighter temperature control and faster recovery times.

Why the Market Dipped But DaVita HealthCare (DVA) Gained Today

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $133.73, denoting a +0.09% change from the preceding trading day.

Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Philips (PHG) Boosts Patient Monitoring With smartQare Deal

Philips (PHG) partners with smartQare to integrate the latter's viQtor solution, boosting its patient monitoring solutions portfolio.

BD's (BDX) Latest Product to Offer Wider Access to Researchers

The latest worldwide commercial availability of BD's (BDX) cell sorters is set to expand researchers' capabilities to transform research and cell-based therapeutic development across numerous fields.

Silk Road Medical's (SILK) New Launch to Aid Its TCAR Portfolio

Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.

Abbott (ABT) Faces Low Testing Demand, Currency Headwinds

Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.

IM Cannabis (IMCC) Expands Business in Germany With New Alliance

The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.

Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC

Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.

AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates

Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.

AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment

AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.

Abbott (ABT) Receives FDA's Approval for the TriClip TEER System

Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.

Sweta Killa headshot

Diagnosing the Economy Ahead of World Health Day: 6 Picks

Similar to the six vital nutrients required for good health, we have examined the six pillars that support the economy and zeroed in on stocks that have a Zacks Rank #1 (Strong Buy) or 2 (Buy) and a higher market cap in their respective sectors.

Henry Schein (HSIC) Buys TriMed to Expand in Orthopedic Space

According to Henry Schein (HSIC), the upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion.

Benjamin Rains headshot

3 Soaring, Highly-Ranked Value Stocks to Buy in April

3 highly-ranked Zacks stocks that offer an attractive combination of impressive valuations, soaring stock prices, and long-term upside in crucial, non-flashy industries.

GE HealthCare's (GEHC) New Launch to Enhance Cardiac Care

GE HealthCare's (GEHC) latest offering is likely to expand access to cardiac care by enabling more medical professionals to be able to capture cardiac images.

Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS

Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.

Reasons to Add Cardinal Health (CAH) to Your Portfolio Now

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now

Ecolab's (ECL) focus on research and development raises optimism about the stock.

Globus Medical (GMED) Gains From New Launches Amid Macro Issues

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Align (ALGN) Debuts Invisalign Palatal Expander in New Markets

Align's (ALGN) Invisalign Palatal Expander system is now available in Australia and New Zealand for skeletal and dental expansion in growing patients.

Veeva Systems (VEEV) Makes Change to Front Office (revised)

Veeva Systems' (VEEV) CFO Brent Bowman steps down, leading analysts to weigh in on the impact and prospects for the cloud-solutions company.